Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros

Kenneth B. Ain

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Differentiated thyroid carcinomas are typically treated with total thyroidectomy as initial therapy. Subsequent radioactive iodine (RAI) ablation destroys post-surgical thyroid remnants, can additionally provide adjuvant therapy of residual and metastatic thyroid cancers, and enhances the sensitivity and specificity of further diagnostic studies. There is current controversy regarding whether a large number of patients, broadly considered to have “low-risk” disease, should be provided RAI ablation. This is consequent to over-reliance on short-term studies, under-appreciation of the value of RAI remnant ablation, and inflation of the side effects of RAI therapy. A balanced assessment of all of these issues provides justification to utilize post-surgical radioiodine ablation, even in cases that are considered low risk on the basis of surgical findings.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
Issue number1
StatePublished - Sep 25 2015

Bibliographical note

Publisher Copyright:
© 2015, Springer Science+Business Media New York (outside the USA).


  • Mortality
  • Radioactive iodine
  • Thyroid carcinoma
  • Toxicity
  • Treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros'. Together they form a unique fingerprint.

Cite this